Overexpression of the CDK inhibitor p16 through an adenovirus vector was shown to inhibit cardiac hypertrophy in vivo, suggesting a novel therapy for pathological cardiac hypertrophy [709]. Here, CDKN2A is linked to cardiac hypertrophy.